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ABSTRACT Mice deﬁcient for granulocyte-macrophage colony-stimulating factor
(GM-CSF/) are highly susceptible to infection with Mycobacterium tuberculosis, and
clinical data have shown that anti-GM-CSF neutralizing antibodies can lead to in-
creased susceptibility to tuberculosis in otherwise healthy people. GM-CSF activates
human and murine macrophages to inhibit intracellular M. tuberculosis growth. We
have previously shown that GM-CSF produced by iNKT cells inhibits growth of M. tu-
berculosis. However, the more general role of T cell-derived GM-CSF during infection
has not been deﬁned and how GM-CSF activates macrophages to inhibit bacterial
growth is unknown. Here we demonstrate that, in addition to nonconventional T
cells, conventional T cells also produce GM-CSF during M. tuberculosis infection. Early
during infection, nonconventional iNKT cells and  T cells are the main source of
GM-CSF, a role subsequently assumed by conventional CD4 T cells as the infection
progresses. M. tuberculosis-speciﬁc T cells producing GM-CSF are also detected in the
peripheral blood of infected people. Under conditions where nonhematopoietic pro-
duction of GM-CSF is deﬁcient, T cell production of GM-CSF is protective and re-
quired for control of M. tuberculosis infection. However, GM-CSF is not required for T
cell-mediated protection in settings where GM-CSF is produced by other cell types.
Finally, using an in vitro macrophage infection model, we demonstrate that GM-CSF
inhibition of M. tuberculosis growth requires the expression of peroxisome
proliferator-activated receptor gamma (PPAR). Thus, we identiﬁed GM-CSF produc-
tion as a novel T cell effector function. These ﬁndings suggest that a strategy aug-
menting T cell production of GM-CSF could enhance host resistance against M. tu-
berculosis.
IMPORTANCE Mycobacterium tuberculosis is the bacterium that causes tuberculosis,
the leading cause of death by any infection worldwide. T cells are critical compo-
nents of the immune response to Mycobacterium tuberculosis. While gamma inter-
feron (IFN-) is a key effector function of T cells during infection, a failed phase IIb
clinical trial and other studies have revealed that IFN- production alone is not sufﬁ-
cient to control M. tuberculosis. In this study, we demonstrate that CD4, CD8, and
nonconventional T cells produce GM-CSF during Mycobacterium tuberculosis infection
in mice and in the peripheral blood of infected humans. Under conditions where
other sources of GM-CSF are absent, T cell production of GM-CSF is protective and is
required for control of infection. GM-CSF activation of macrophages to limit bacterial
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growth requires host expression of the transcription factor PPAR. The identiﬁcation
of GM-CSF production as a T cell effector function may inform future host-directed
therapy or vaccine designs.
KEYWORDS GM-CSF, Mycobacterium tuberculosis, T cells, cytokines, lung infection,
macrophages
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is a bacteriumthat latently infects nearly one-third of the world’s population, causing active
disease in 10% of individuals (1). Bacillus Calmette-Guérin (BCG), the only approved
vaccine available against TB, has variable efﬁcacy in different populations, and it is
generally agreed that a better vaccine is needed (2). Thus, it is crucial to identify
protective immune mechanisms against M. tuberculosis that might help in the design
of future therapeutics or vaccines.
More than three decades ago, it was demonstrated that CD4 and CD8 T cells
were required for an effective immune response to M. tuberculosis (3–5). Similarly,
gamma interferon (IFN-) was identiﬁed as a key cytokine that leads to inhibition and
killing ofM. tuberculosis through induction of nitric oxide (6), phagolysosomal fusion (7),
autophagy (8), and vitamin D receptor expression (9), although T cell production of
IFN- has only recently been linked to M. tuberculosis control (10). Despite the central
role of IFN-, there is evidence that too much IFN-may be detrimental and that T cells
can control M. tuberculosis growth in vivo independently of IFN- (11–13). The role of
IFN- in people is more difﬁcult to discern. Importantly, a phase IIb clinical trial testing
a heterologous prime-boost strategy of BCG followed by a modiﬁed vaccinia Ankara
virus expressing M. tuberculosis antigen 85 (MVA85) increased IFN- production by
antigen-speciﬁc T cells but had no impact on protection from M. tuberculosis infection
over 2 years (14). Collectively, these data suggest that T cell-mediated mechanisms of
protection other than IFN- production may mediate protection.
Apart from IFN- production, there are several other T cell effector functions that
contribute to an antimicrobial response. Mice lacking tumor necrosis factor (TNF) are
highly susceptible to M. tuberculosis infection (15), and T cell production of TNF has
been shown to be critical for protection (16). Interleukin-17 (IL-17) has also been shown
to have an important role in controlling M. tuberculosis and in effective granuloma
formation during the early phase of infection, but too much IL-17 can have detrimental
effects by promoting immunopathology (11, 17, 18). In addition, cytolytic activity by
CD8 T cells has been shown to contribute to protection in both mice and humans
(19–22). Identifying additional effector cytokines produced by T cells during M. tuber-
culosis infection could provide novel immunotherapy targets and new potential corre-
lates of protection for vaccine evaluation.
We previously showed that iNKT cell production of granulocyte-macrophage colony-
stimulating factor (GM-CSF) contributes to their ability to restrict bacterial growth in
vitro and that GM-CSF treatment of macrophages restricts M. tuberculosis growth in
murine cells (23). GM-CSF treatment of human macrophages inhibits intracellular
growth of M. tuberculosis and Mycobacterium avium (24–26), and GM-CSF/ mice are
highly susceptible to M. tuberculosis (27, 28). However, GM-CSF production is not
restricted to iNKT cells; it is produced by many different cell types, including leukocytes
(29, 30), epithelial cells (31), and ﬁbroblasts (32), and it was originally identiﬁed for its
role in maturation of both macrophages and granulocytes from bone marrow precursor
cells in vitro (33). GM-CSF is commonly used to differentiate dendritic cells in vitro (34),
and it is used clinically to boost myeloid recovery after chemotherapy. Mice lacking
GM-CSF develop normally and show no signs of abnormal steady-state hematopoiesis
(35, 36). However, these mice do have dramatic defects in lung function, which can be
explained by a failure of alveolar macrophages to develop (37, 38). An absence of
GM-CSF leads to dysregulation of surfactant recycling in alveolar macrophages, gen-
erating a pulmonary inﬂammatory defect that resembles the human disease pulmonary
alveolar proteinosis (PAP). Overexpression of GM-CSF by type II epithelial cells after
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insertion of a GM-CSF transgene on a surfactant protein C promoter abrogated the
development of PAP in GM-CSF/ mice (39). These and other studies led to the idea
that pulmonary epithelial cells are the main producers of GM-CSF in the lung, and
GM-CSF is important for normal lung homeostasis. Interestingly, overexpression of
GM-CSF in epithelial cells in GM-CSF/ mice led to only partial rescue of M. tubercu-
losis susceptibility, suggesting that GM-CSF production by other cells may also con-
tribute to protection (27, 28). Additionally, clinical studies have found that the presence
of anti-GM-CSF autoantibodies that block GM-CSF function are associated with suscep-
tibility to both cryptococcal meningitis and pulmonary TB in otherwise healthy subjects
(40), indicating that GM-CSF may also participate in host defense against infection in
people. In contrast, immunotherapy that induces GM-CSF production was recently
shown to be effective against both drug-resistant and drug-sensitive M. tuberculosis
infection in mice (41, 42).
Here, we tested the hypothesis that T cell production of GM-CSF contributes to host
resistance to M. tuberculosis. We found that numerous T cell subsets, including both
conventional and unconventional T cells, produce GM-CSF after infection. T cell pro-
duction of GM-CSF was not required for the T cell ability to transfer protection to
susceptible hosts when other cell types already produced GM-CSF. However, in the
absence of other sources of GM-CSF, GM-CSF production by hematopoietic cells and
speciﬁcally T cells can contribute to host resistance. GM-CSF is produced by human T
cells and can have additive protective effects with IFN- toward M. tuberculosis-infected
macrophages. While GM-CSF induces numerous changes to mature macrophages, we
discovered that GM-CSF control of M. tuberculosis growth requires peroxisome
proliferator-activated receptor gamma (PPAR) expression. PPAR is a nuclear receptor
that controls cellular lipid and glucose metabolism, and regulation of PPAR by GM-CSF
has been shown to be essential for alveolar macrophage development and surfactant
homeostasis in the lung (38, 43). These results show that T cell production of GM-CSF
contributes to control of M. tuberculosis infection in the absence of other sources of
GM-CSF, that multiple T cell subsets make GM-CSF in the lung over the course of
infection, and that GM-CSF can act directly on infected macrophages through a
pathway requiring PPAR to limit bacterial growth.
RESULTS
GM-CSF production is increased in the lungs during M. tuberculosis infection.
To determine the overall production of GM-CSF in the lung during M. tuberculosis
infection, we measured GM-CSF concentrations in lung homogenates. A small amount
of GM-CSF was detected in the lungs of uninfected mice, and the amount increased
following M. tuberculosis infection (Fig. 1). The kinetics of GM-CSF accumulation in the
lungs of M. tuberculosis-infected mice roughly coincided with the development of T cell
immunity and inﬂammatory changes in the lung, and it paralleled IFN- production, a
cytokine predominantly made by T cells (44). Of note, GM-CSF was more abundant than
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FIG 1 GM-CSF production in the lung increases over the course of M. tuberculosis infection. GM-CSF was
measured in a Bioplex immunoassay in lung homogenates at certain weeks post-aerosol infection with
the Erdman strain in WT C57BL/6J mice. GM-CSF and IFN- protein levels were normalized per lung. **,
P 0.01; ***, P 0.001; ****, P 0.0001 (compared to previous time point). #, P 0.05 for GM-CSF versus
IFN-.
T Cell Production of GM-CSF during Tuberculosis ®
September/October 2017 Volume 8 Issue 5 e01514-17 mbio.asm.org 3
 
m
bio.asm
.org
 o
n
 D
ecem
ber 27, 2017 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
IFN-, which is one of the classic markers of T cell immunity to M. tuberculosis. The
increased levels of GM-CSF persisted in the lung during chronic M. tuberculosis, with an
increase of 2.0-fold  0.3-fold (mean  standard error of the mean [SEM]) at 4 weeks,
5.0-fold  0.2-fold at 12 weeks, and 5.1-fold  0.1-fold at 24 weeks above that in lungs
of uninfected mice. These data conﬁrmed that GM-CSF production accumulates in the
lung over the course of infection (45), and the kinetics suggest that its production
increases as an adaptive immune response develops in the lungs.
GM-CSF production by both radioresistant and radiosensitive cells contributes
to host resistance against TB. In previous studies, the susceptibility of GM-CSF/
mice to M. tuberculosis was shown to be partially rescued if GM-CSF was overexpressed
under the control of the surfactant protein C promoter, a gene thought to be speciﬁc
for type II pulmonary epithelial cells (27, 28). Under those conditions, survival was
prolonged but not completely rescued. Therefore, we hypothesized that additional cell
types could be important and necessary sources of GM-CSF during TB. Speciﬁcally, we
considered whether GM-CSF production by epithelial cells and other nonhematopoietic
cells (generally radioresistant) was sufﬁcient for host defense against M. tuberculosis or
whether hematopoietic cells (generally radiosensitive) were also required. To test this
hypothesis, reciprocal radiation chimeric mice using wild-type (WT) and GM-CSF/
donor bone marrow (BM) and recipient mice were produced. Transferring GM-CSF/
BM into GM-CSF/ recipients (KO ¡ KO) resulted in chimeric mice that were more
susceptible than chimeric mice in which WT BM was transferred to WT recipient mice
(WT ¡ WT), based on their lung bacterial burden 4 weeks after M. tuberculosis
challenge (Fig. 2A). Chimeras made by transferring GM-CSF/ BM into WT recipients
(KO¡ WT) were similarly resistant as WT¡ WT chimeric mice, indicating that GM-CSF
production by radioresistant cells was sufﬁcient to confer host resistance, which is
consistent with the established role for GM-CSF production by pulmonary epithelial
cells. Chimeric mice generated by injecting WT BM into GM-CSF/ recipients (WT ¡
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FIG 2 GM-CSF production by either radioresistant or radiosensitive cells promotes mycobacterial
control. (A and C) Reciprocal radiation chimeric mice (donor BM ¡ recipient) were allowed to reconsti-
tute for 8 weeks and then challenged with aerosolized M. tuberculosis, and lung (A) and spleen (C) CFU
were determined after 4 weeks. Each group contained 4 to 5 mice, and data were combined from 2
independent experiments (results of the ﬁrst experiment are shown as open symbols, and those from the
second experiment are shown as closed symbols). A one-way ANOVA was used. *, P  0.05. See Table
S1 for statistical analysis of each experiment’s data, analyzed separately and also combined. (B and D) A
third experiment was done to compare the how WT ¡ KO and KO ¡ KO BM chimeras controlled
M. tuberculosis infection in the lungs (B) and spleen (D). The groups contained 7 and 5 mice, respectively.
Bars represent means  SEM. Analysis was performed using an unpaired t test. *, P  0.05 (WT versus
C57BL/6 mice and KO versus GM-CSF/ mice).
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KO) trended toward being more resistant than the KO¡ KO mice in two independent
experiments, although this result was not statistically signiﬁcant. When the experiment
was repeated with greater statistical power (n  5 to 7 mice/group), the WT ¡ KO
chimeras controlled M. tuberculosis lung infection better than KO¡ KO chimeras (P 
0.05) (Fig. 2B). Of note, there were no differences in bacterial control within the spleen
between experimental groups (Fig. 2C and D). These results showed that GM-CSF is
required for control of M. tuberculosis in the lungs but is dispensable for control in the
spleen (27). Importantly, these results indicate that GM-CSF produced by hematopoietic
cells can contribute to resistance against M. tuberculosis.
Multiple T cell subsets produce GM-CSF during M. tuberculosis infection. To
directly test whether T cells produce GM-CSF during M. tuberculosis infection, we
performed intracellular cytokine staining (ICS) analysis of lung samples of uninfected or
M. tuberculosis-infected mice at multiple time points. To determine which cells were
actively secreting GM-CSF in the lung, rather than detecting the cells capable of
secreting the cytokine, ICS was performed in the presence of IL-2 and brefeldin A
without further antigen exposure or other stimulation. Separate staining panels were
used to assess the four major T cell subsets, which were gated following doublet and
autoﬂuorescence exclusion: iNKT cells (T cell receptor  [TCR-] CD1d tetramer), 
T cells (CD3 TCR- TCR-), CD4 T cells (TCR- CD4 CD8), and CD8 T cells
(TCR- CD4 CD8) (Fig. 3A). We found that all 4 subsets produced GM-CSF during
infection (Fig. 3B). The relative proportions of each of the T cell subsets producing
GM-CSF at each time point were calculated. A small but detectable number of iNKT cells
and  T cells produced GM-CSF early during infection (0 to 2 weeks) (Fig. 3C). CD4
T cells began to dominate the GM-CSF response between weeks 3 and 4, while CD8
T cells were not a signiﬁcant source of GM-CSF until week 8 postinfection. IFN-
production by these subsets was concurrently assessed for comparison (Fig. 3D). In
contrast to GM-CSF, CD4 T cells were clearly the dominant IFN- producers at most
time points (Fig. 3E). Dual GM-CSF/IFN--producing cells were not detected until week
3 and were mostly CD4 and CD8 T cells (Fig. 3F).
These data showed that both innate-like and adaptive T cell subsets produce
GM-CSF in the lung in response to M. tuberculosis infection. All four T cell subsets
displayed statistically signiﬁcant increases in GM-CSF production during infection
compared to baseline (week 0, uninfected) (iNKT cells and  T cells, P  0.0001; CD4
T cells, P  0.0006; CD8 T cells, P  0.0001; one-way analysis of variance [ANOVA]
with Dunnett’s posttest). In addition, these data indicated that although GM-CSF and
IFN- production are regulated differently during infection, these pathways converge
as the immune response to M. tuberculosis matures and signiﬁcant numbers of dual
cytokine-producing T cells begin to accumulate in the lung.
GM-CSF production by T cells can mediate protection in vivo. To determine the
relative importance of GM-CSF production by T cells for control of M. tuberculosis
infection, we used two different adoptive transfer strategies. First, bulk T cells from
uninfected WT or GM-CSF/ mice were transferred into RAG/ mice, which were
then infected with a low dose of aerosolized M. tuberculosis (Fig. 4A). Both WT and
GM-CSF/ CD4 T cells transferred similar amounts of protection to immunodeﬁcient
RAG/ mice (Fig. 4B), and we conﬁrmed, by intracellular cytokine staining, that WT
and GM-CSF/ CD4 T cells were both able to produce IFN- after transfer in response
to either antigen or anti-CD3/CD28 stimulation, independently of GM-CSF production
(Fig. 4C). In some experiments, WT CD4 T cells were more efﬁcient than GM-CSF/
CD4 T cells at transferring protection; however, these differences were not always
statistically signiﬁcant. An important caveat to this approach is that in this model
recipient mice still have an intact non-T cell source of GM-CSF, including lung epithelial
cells, analogous to radioresistant cells. Indeed, both we (Fig. 2) and others (27, 28) have
shown that such cells are crucial for protection in the absence of T cell production of
GM-CSF. Therefore, we tested a second model in which the only source of GM-CSF was
the transferred T cells.
T Cell Production of GM-CSF during Tuberculosis ®
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To study the protective capacity of T cell-derived GM-CSF, we transferred WT or
GM-CSF/ CD4 effector T cells, obtained from M. tuberculosis-infected WT or GM-
CSF/ mice, into sublethally irradiated GM-CSF/ mice (Fig. 4D). In this experiment,
we transferred lung-derived CD4 T cells from previously infected mice in order to
transfer the greatest number of M. tuberculosis antigen-speciﬁc T cells possible, since
their population is signiﬁcantly expanded in infected mice compared to naive mice.
This adoptive transfer of immune T cells was adapted from previously published
adoptive transfer strategies (46, 47). GM-CSF/ effector CD4 T cells transferred to
GM-CSF/ mice did not confer protection in the lung or the spleen (Fig. 4E and data
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FIG 3 Multiple T cell subsets produce GM-CSF in the lung during M. tuberculosis infection. (A) Representative ﬂow cytometry plots after gating of iNKT cells,
 T cells, and CD4 and CD8 T cells. Controls for CD1d tetramer and GM-CSF and IFN- ICS staining are included. (B and C) Absolute cell numbers (B) and
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not shown). In fact, they exacerbated disease and growth of M. tuberculosis. In contrast,
WT effector CD4 T cells transferred to GM-CSF/ mice conferred signiﬁcant protec-
tion: there was an ~1.7 Δlog10 decreased bacterial burden compared to GM-CSF/
mice that did not receive T cell transfer and ~2.5 Δlog10 decreased burden compared
to mice that received GM-CSF/ effector CD4 T cells (Fig. 4E). The inability of the
GM-CSF/ effector CD4 T cells to transfer protection led us to verify the quality of the
immune response in the donor mice. We measured the frequency of ESAT63-17-speciﬁc
CD4 T cells among the puriﬁed CD4 T cells by using tetramers. We found that
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or GM-CSF/ T cells into RAG/ recipient mice, followed by M. tuberculosis aerosol infection. (B) CFU in lungs
4 weeks postinfection after WT or GM-CSF/ T cells were transferred into RAG/ recipients. Data are represen-
tative of ﬁve independent experiments. (C) Percentage of CD4 T cells producing IFN- or GM-CSF after 5 h of
ESAT61-20 peptide stimulation or anti-CD3/anti-CD28 stimulation with brefeldin A and IL-2 at 4 weeks postinfection.
(D) Experimental strategy for adoptive transfer experiments using sublethally irradiated GM-CSF/ mice as
recipients, who were then infected with M. tuberculosis via aerosol. (E) CFU in lungs 4 weeks postinfection after WT
or GM-CSF/ CD4 T cells were transferred into GM-CSF/ recipients. Data were compiled from 4 independent
infections with a total of n 16 to 19 mice per condition. (F) Frequency of ESAT63-17 tetramer-positive CD4 T cells
from donor WT and GM-CSF/ infected mice 4 weeks after sublethal irradiation, adoptive transfer, and aerosol
infection. (G) Experimental strategy for adoptive cotransfer of CD4 T cells from donor WT and GM-CSF/ Thy1.1
recipients 4 weeks after infection (at a 1:1 ratio) with M. tuberculosis infection via aerosol. (H) Origin of CD4 T cells
based on congenic markers 4 weeks after infection. (I and J) Frequency of ESAT63-17-positive (I) or Ag85b241-256
tetramer-positive (J) CD4 T cells among total host (e.g., endogenous), WT, or KO CD4 T cells. Statistical testing
was performed by using a paired 1-way ANOVA. *, P  0.05; **, P  0.01; ****, P  0.0001. Error bars indicate SEM.
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transferred CD4 T cells from both donor WT and GM-CSF/ infected mice had similar
frequencies of ESAT63-17-speciﬁc CD4 T cells (2.0% to 2.5% of the CD4 T cells).
Similarly, at the 4-week time point, the median frequency of ESAT63-17-speciﬁc CD4 T
cells was slightly higher among recipients that received GM-CSF/ CD4 T cells than
mice that received WT CD4 T cells (9.8% versus 7.4%), possibly reﬂecting the higher
lung bacterial burden in the former group, but the difference was not statistically
different between the subjects that received WT versus GM-CSF/ CD4 T cells
(Fig. 4F).
To further verify that the GM-CSF/ CD4 T cells were ﬁt and could expand
following M. tuberculosis challenge, we cotransferred congenically marked WT (CD45.1)
or GM-CSF/ (CD45.2) CD4 effector T cells obtained from M. tuberculosis-infected WT
or GM-CSF/mice into sublethally irradiated CD90.1 recipient mice. After transfer, the
mice were infected, and we measured the relative ﬁtness of the T cells 4 weeks later
(Fig. 4G). We were able to identify recipient, WT donor, and GM-CSF/ donor CD4 T
cells (Fig. 4H). The WT CD4 T cells were more abundant than GM-CSF/ CD4 T cells,
with a frequency of 34% versus 23% (P  0.0004, paired t test) (Fig. 4H). However, the
relative frequency of antigen-speciﬁc CD4 T cells derived from each genotype differed
depending on the epitope: WT CD4 T cells dominated the response to ESAT6, while
GM-CSF/ CD4 T cells more frequently recognized Ag85b (Fig. 4I and J). The results
of the cotransfer experiment suggest that GM-CSF/ T cells do not have a broad
defect in their ability to expand and generate antigen-speciﬁc responses that would
explain their failure to control infection when transferred.
Taken together, these different adoptive transfer experiments indicate that while
GM-CSF is not required for T cell-mediated protection in a setting where GM-CSF is
produced by other cell types, T cell production of GM-CSF can be crucial for the control
of M. tuberculosis growth in environments where nonhematopoietic GM-CSF produc-
tion is suboptimal.
GM-CSF production by human T cells. To investigate whether human T cells
produce GM-CSF during infection, peripheral blood mononuclear cells (PBMC) from
active TB patients (TB) or healthy controls (HC) were stimulated or not with M. tuber-
culosis lysate, and the production levels of GM-CSF and IFN- by CD4 T cells and CD4
T cells were determined by ﬂow cytometry (see Fig. S1 in the supplemental material for
the gating strategy). CD4 T cells consist primarily of classical CD8 T cells but also
include CD4 CD8 T cells, such as iNKT cells and  T cells. GM-CSF was detected in
stimulated CD4 and CD4 T cells from HC and TB subjects, compared to an isotype
control (data not shown) or under unstimulated conditions (Fig. 5A). In addition,
stimulation with phorbol myristate acetate (PMA) and ionomycin led to a substantial
proportion of CD4 T cells producing GM-CSF, either alone or in combination with
IFN-. CD4 T cells also produced GM-CSF under these stimulation conditions (Fig. 5A).
We next determined whether GM-CSF production discriminated between HC and TB
subjects (Fig. 5B). Although stimulation with M. tuberculosis lysate led to an increase in
GM-CSF production by CD4 T cells from TB patients, GM-CSF production was not
signiﬁcantly elevated compared to HC subjects. In contrast, CD4 T cell production of
IFN- was signiﬁcantly increased in TB patients compared to HC, both for CD4 T cells
that only produced IFN- (Fig. 5B, left) as well as the total percentage of IFN--
producing CD4 T cells, with or without GM-CSF (Fig. 5B, right), as anticipated.
Somewhat unexpectedly, the percentage of CD4 T cells producing GM-CSF after
stimulation with the M. tuberculosis lysate was signiﬁcantly increased in TB patients
compared to HC subjects both for CD4 T cells that only produced GM-CSF (Fig. 5C,
left) and for the total percentage of GM-CSF-producing CD4 T cells (Fig. 5C, right).
These data show that both CD4 and CD4 T cells produce GM-CSF as part of the
human T cell response toM. tuberculosis and that inclusion of GM-CSF in immunoassays
may increase their predictive power (48).
GM-CSF and IFN- have an additive effect in promoting macrophage control of
intracellular bacterial replication. GM-CSF activates macrophages to limit intracellu-
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lar growth of M. avium and M. tuberculosis (24–26). The ﬁnding that a signiﬁcant
proportion of CD4 T cells produced both GM-CSF and IFN-, in both mice and
humans, led us to hypothesize that GM-CSF and IFN- work together to activate
macrophages to limit intracellular bacterial growth. Using an in vitro macrophage
infection model (23), we tested whether the antimicrobial effects of GM-CSF and IFN-
were additive (Fig. 6). Both GM-CSF and IFN- were individually able to inhibit M. tu-
berculosis growth at higher cytokine concentrations (such as 10 ng/ml). However, at
lower concentrations (0.1 ng/ml), the combination of GM-CSF and IFN- led to a
statistically signiﬁcant decrease in CFU compared to the efﬁcacy of each cytokine alone.
The lower cytokine concentrations may be more representative of the concentrations
encountered by infected cells in the lung, and under these conditions, GM-CSF and
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FIG 5 GM-CSF production by human T cells. (A) Representative ﬂow cytometric analysis results for
GM-CSF and IFN- production by unstimulated human peripheral blood CD4 and CD4 T cells, or after
stimulation with M. tuberculosis lysate (Mtb lysate), or after treatment with PMA plus ionomycin (P  I).
(B and C) The frequency of CD4 (B) or CD4 (C) T cells producing GM-CSF only, both GM-CSF and IFN-,
or IFN- only (left), or the total GM-CSF or total IFN- (right), from healthy controls (n  9) or active TB
patients (n  9) stimulated with M. tuberculosis lysate. Red circles, HC; blue circles, TB patients. Lines
indicate means  standard deviations. Statistical testing was performed with a two-way ANOVA. *, P 
0.05; **, P  0.01; ****, P  0.0001.
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IFN- appear to have an additive effect. Although the results do not reveal a clear
synergistic effect between these cytokines, further investigation into the antimicrobial
mechanism of GM-CSF may reveal mechanistic connections with IFN-.
GM-CSF antimicrobial activity requires PPAR expression in macrophages. To
identify the antimicrobial mechanism of GM-CSF, we ﬁrst tested a number of pathways
previously reported to be modulated by GM-CSF (49–51). Treatment of macrophages
with recombinant GM-CSF did not induce nitric oxide or reactive oxygen species (ROS)
production or increase the rate of phagocytosis (data not shown). To examine the effect
of GM-CSF more broadly, we focused our investigation on transcription factors that
might be required for GM-CSF-mediated control of M. tuberculosis growth within
macrophages. PPAR is a nuclear receptor that regulates cellular lipid metabolism and
plays an important role in lipid recycling and surfactant catabolism, especially in
alveolar macrophages (43, 52–54). Furthermore, PPAR has speciﬁcally been linked to
GM-CSF function based on the ﬁnding that patients with (e.g., PAP) often have
autoantibodies to GM-CSF or mutations in the receptor for GM-CSF, which leads to
dysregulated surfactant metabolism by alveolar macrophages. Importantly, the PAP-
like phenotype of GM-CSF/ animals is rescued by lentivirus-directed overexpression
of PPAR, leading to net cholesterol efﬂux and reduction of lipid accumulation in
alveolar macrophages (55). Therefore, we hypothesized that PPAR mediates the
protective effects of GM-CSF in macrophages.
H37Rv-infected WT and PPAR/ (PPARﬂ/ﬂ; LysM-cre) peritoneal macrophages
were treated with recombinant GM-CSF. While GM-CSF led to inhibition of bacterial
growth in WT macrophages, no inhibition was observed for PPAR/ macrophages
(Fig. 7A). IFN-/TNF treatment, a positive control for bacterial growth restriction, led to
inhibition of bacterial growth in both macrophages types. When the percent CFU
reduction was calculated for 4 independent experiments, there was a statistically
signiﬁcant difference for the CFU reduction between WT and PPAR/ macrophages
for all GM-CSF doses between 0.01 and 10 ng/ml (Fig. 7B). Similar results were found for
comparisons between PPAR/ (PPARﬂ/ﬂ; LysM-cre) and PPARﬂ/ﬂ control (PPARﬂ/ﬂ;
no cre expression) macrophages (data not shown). These data suggest that PPAR
signaling is involved in the antimicrobial effector pathway stimulated by GM-CSF in
M. tuberculosis-infected macrophages.
DISCUSSION
While it is well-understood that T cells, particularly CD4 T cells, are required to
control M. tuberculosis infection, the particular T cell effector functions that lead to
control of infection continue to be debated. Indeed, the paradigm that CD4 T cell
production of IFN- is the crucial link between T cell immunity and control of TB has
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been broken (56). Although IFN- is crucial for host resistance and CD4 T cell
production of IFN- can be essential (10), it is clear that IFN--independent mechanisms
of host protection exist and IFN- production by CD4 T cells is not sufﬁcient on its
own for protection (11, 12, 57). Furthermore, at least some of the host-protective nature
of IFN- may be based on an immunoregulatory role (57). Regardless, it is increasingly
appreciated that IFN- is a better correlate of bacterial load than protection (58) and
that, under certain circumstances, too much IFN- can be detrimental (13). Given the
rapidly changing views on the role of IFN-, what T cell effector molecules activate
macrophages to restrict intracellular M. tuberculosis growth?
We previously made the unexpected observation that iNKT cells control intracellular
M. tuberculosis growth (59) by an IFN--independent mechanism (23). By taking ad-
vantage of our in vitro system, we identiﬁed GM-CSF as an iNKT cell product that
activates macrophages to control infection (23). Indeed, this ﬁnding veriﬁed previous
reports that GM-CSF has antimycobacterial activity, as originally described by Denis
et al. (26). In addition, GM-CSF expression adenovirus therapy was recently shown to
have some efﬁcacy against both drug-sensitive and drug-resistant M. tuberculosis
infection in mice (41). Furthermore, the GM-CSF/ mouse is highly susceptible to
M. tuberculosis infection, with a median survival time of 4 to 5 weeks (27, 28). However,
the role of GM-CSF is complicated, as it has pleiotropic effects with a particularly
instrumental role in alveolar macrophage development in the lung (60), although
surprisingly, other myeloid cell populations in the GM-CSF/ mouse are relatively
normal (36). A key function for GM-CSF in lung physiology is its role in surfactant
recycling, and the GM-CSF/ mouse develops a pulmonary syndrome that resembles
the human disease PAP, which has been associated with the production of anti-GM-CSF
antibodies. Therefore, it has been uncertain whether the susceptibility of the GM-
CSF/ mouse is due to the lack of mature alveolar macrophages, abnormal surfactant
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metabolism, or some role of GM-CSF in adaptive immunity. The ﬁnding by Higgins et
al., which was conﬁrmed herein, that lung GM-CSF increases during active tuberculosis
raises the possibility that GM-CSF is produced as part of the acquired immune response
duringM. tuberculosis infection (45). Indeed, the kinetics of GM-CSF accumulation in the
lung largely mirrors the kinetics of T cell recruitment following priming.
Our ﬁnding that iNKT cell production of GM-CSF contributes to antimycobacterial
immunity in an in vitro model with M. tuberculosis-infected macrophages supports this
concept (23). We also detected that iNKT cells in the lungs of M. tuberculosis-infected
mice produced GM-CSF in a CD1d-restricted manner. However, since CD1d-restricted T
cells are not required for host resistance against M. tuberculosis infection in the mouse
model (61, 62), we wondered whether the production of GM-CSF by multiple T cell
subsets might make an important contribution to protection against M. tuberculosis
infection. Expression of GM-CSF by type II pulmonary epithelial cells partially corrected
the susceptibility of GM-CSF/ mice (27, 28). Indeed, our result showing that GM-CSF
production by radioresistant cells (e.g., nonhematopoietic cells) was sufﬁcient to confer
host resistance is consistent with these previous reports. However, we also found that
GM-CSF production by radiosensitive cells was capable of conferring host resistance. In
fact, we showed that different types of T cells produce GM-CSF early after infection,
most prominently  T cells and iNKT cells. As immunity to M. tuberculosis becomes
established, GM-CSF production by CD4 T cells dominates.
We next asked whether GM-CSF production by effector T cells is important for T
cell-mediated protection against M. tuberculosis. The straightforward approach of
transferring naive splenic T cells from WT or GM-CSF/ mice into RAG/ mice gave
us somewhat inconclusive results. In general, both populations of T cells protected
RAG/ mice, and in some experiments, WT T cells were more effective. These transfer
experiments suggest that GM-CSF is not required for T cell-mediated protection.
However, we realized that these experiments might be confounded by the fact that
GM-CSF production by radioresistant cells can mask the effect of GM-CSF produced by
T cells. Because of these concerns, we tested a second model. We infected WT or
GM-CSF/ mice to ﬁrst generate effector T cells. CD4 T cells were then puriﬁed from
the lungs of these mice at around 4 weeks of infection, near the peak of the T cell
response. These T cells were then adoptively transferred into GM-CSF/ mice, which
were then challenged with M. tuberculosis. Under these conditions, WT CD4 T cells
transferred protection, and this protection was signiﬁcantly better than that after
transfer of GM-CSF/ CD4 T cells. Surprisingly, transfer of GM-CSF/ CD4 T cells
generally led to increased bacterial growth. Although our experiments were performed
in sublethally irradiated mice, T cells transferred into unirradiated GM-CSF/ recipient
mice produced the same results. One interpretation is that GM-CSF directly induces
antimicrobial activity in macrophages (as we observed for iNKT cells). Alternatively,
GM-CSF may be important in T cell priming, differentiation, and expansion into
antigen-speciﬁc effector T cells. To test these various interpretations, we cotransferred
WT and GM-CSF/ CD4 T cells from M. tuberculosis-infected mice into sublethally
irradiated recipients and monitored the ability of the T cell population to expand during
infection. While the GM-CSF/ CD4 T cells expanded to a slightly lower frequency
overall than the WT CD4 T cells after 4 weeks, their ability to expand in an antigen-
speciﬁc manner was highly dependent on the antigen. ESAT6-speciﬁc GM-CSF/
CD4 T cells were observed at a lower frequency than their WT counterparts, but
Ag85b-speciﬁc GM-CSF/ CD4 T cells were found at a higher frequency than WT
cells. This result is intriguing, because a recent study showed that in both mice and
humans the functions of ESAT6 and Ag85b CD4 T cells are highly distinct and a direct
result of antigen availability over the course of infection (63). Our results do not
eliminate the possibility that GM-CSF production by T cells have both direct effects to
activate macrophages to kill M. tuberculosis and indirect (i.e., regulatory) effects that
promote host resistance.
We interpret these various data to mean that in a GM-CSF-replete environment,
for example, a WT mouse with a functioning epithelial compartment, T cell pro-
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duction of GM-CSF is not absolutely required for protection. However, if there is a
deﬁcit in local GM-CSF production, because of disrupted epithelium, for example, T
cell production of GM-CSF can become crucial for bacterial control. In most hosts,
both IFN- and GM-CSF will be present in the lung, whether made by the same cell
type (e.g., T cells) or different cells (e.g., T cells and epithelial cells). Therefore, we
tested whether the antibacterial activity that IFN- and GM-CSF stimulate in macro-
phages was additive. In general, we found that at lower concentrations of cytokines,
IFN- and GM-CSF had an additive effect that is possibly synergistic. This is important,
as it implies that distinct molecular pathways are activated by these two cytokines.
It was notable to us that in the reciprocal radiation chimeric mouse experiments, the
presence of GM-CSF-producing cells had an effect on the bacterial burden in the lung,
but not in the spleen. This suggested that GM-CSF has a protective function during
M. tuberculosis infection that is lung speciﬁc. Based on the established link between
GM-CSF and PPAR in patients with PAP and in GM-CSF/ mice (38, 55, 64, 65), the
link between anti-GM-CSF antibodies and mycobacterial infection (40), and the role of
PPAR in innate immunity to mycobacteria (66–68), we considered whether the mac-
rophage effector function of GM-CSF is associated with PPAR expression. In our model,
the antibacterial action of GM-CSF is absolutely dependent upon PPAR expression.
GM-CSF has a variety of actions on different cell types, including phagocytosis stimu-
lation, lipid body formation, and nitric oxide (NO) induction. Sorting out which of these
functions contributes to intracellular control of M. tuberculosis growth is difﬁcult, since
many of these cellular processes are known to affect bacterial survival. While some of
these functions, like phagocytosis, NO, and ROS production, were not increased in
primary peritoneal macrophages after GM-CSF treatment, other functions, like lipid
body formation and cell growth and survival, were increased after GM-CSF treatment
but were not dependent on PPAR. This allowed us to rule out many of the effector
functions previously attributed to GM-CSF, although we have not yet pinpointed the
pathway(s) downstream of PPAR that is critical for GM-CSF action. Although the
consequences of GM-CSF signaling on PPAR could vary based on macrophage sub-
type and baseline expression of PPAR (69), the effect of GM-CSF deﬁciency on
PPAR-regulated genes is similar in alveolar and peritoneal macrophages (70). Charac-
terization of this pathway has been made more difﬁcult by the fact that previous
studies have shown that PPAR plays a critical role in the development of alveolar
macrophages in the lung. LysM-cre/PPARﬂ/ﬂ mice have relatively normal numbers of
alveolar macrophages but go on to develop a mild form of pulmonary alveolar
proteinosis as they age (4 months) (38,71). A shortcoming of our study is that we used
thioglycolate-elicited peritoneal macrophages instead of alveolar macrophages. The
large number of macrophages needed for the CFU assay makes it impractical to use
alveolar macrophages.
The strongest evidence that GM-CSF is essential for host defense against infection
in people comes from clinical observations linking the presence of anti-GM-CSF auto-
antibodies with susceptibility to cryptococcal meningitis and pulmonary TB (40). We
hypothesized that GM-CSF production might be part of the human T cell response
against mycobacteria. In a pilot study, we evaluated whether differences existed in the
capacity of T cells from healthy subjects that were free of TB disease versus the
capacities of the T cells in patients diagnosed with pulmonary TB to produce GM-CSF.
Both CD4 and CD4 T cells from subjects with active disease produced GM-CSF after
stimulation with M. tuberculosis lysate. Some T cells produced only GM-CSF and others
produced GM-CSF and IFN-, suggesting that they may represent two distinct T cell
subsets (72). Interestingly, GM-CSF production by CD4 T cells was greater in TB
patients than in HC. While the speciﬁc human CD4 T cell subsets that produce GM-CSF
in response toM. tuberculosis (e.g., classical CD8 T cells, iNKT cells,  T cells) could not
be identiﬁed here, these results showed that GM-CSF is produced by T cells as part of
the immune response to M. tuberculosis in people. A potential confounder with the
study is that the healthy subjects were presumed to be vaccinated with BCG, and T cells
elicited by BCG may have also recognized antigens present in the M. tuberculosis
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lysates. We hypothesize that GM-CSF has a role in controlling infection, and hence it
could be predicted to be more abundant in subjects that are latently infected. Another
possibility is that GM-CSF-producing T cells are more abundant during the early stages
of infection, as part of an initial Th17 response (73), and skewing toward a Th1 response
may lead to the loss of GM-CSF production by CD4 T cells (74). Relatively little is
understood about the regulation of GM-CSF production by T cells. There does not
appear to be a master regulator that programs GM-CSF production, although recently
a subset of T cells was described in which GM-CSF was the dominant cytokine (72).
Importantly, although GM-CSF is associated with Th17 responses in mice, it appears to
be associated with Th1 responses in humans (75). Nevertheless, GM-CSF is an important
cytokine made by T cells, and it has a crucial role in the pathogenicity of autoreactive
Th1 or Th17 cell during autoimmune neurological disease. We hypothesize that gen-
eration ofM. tuberculosis-speciﬁc T cells that can make GM-CSF may enhance protection
against M. tuberculosis infection. We envision a role for GM-CSF either in host-directed
therapy or possibly in the development of vaccines that elicit GM-CSF-producing T cells.
MATERIALS AND METHODS
Ethics statement. All animal experiments were performed in accordance with guidelines of the
Ofﬁce of Laboratory Animal Welfare and the Public Health Service Policy on Humane Care and Use of
Laboratory Animals. The protocols that adhered to these guidelines were approved by the Dana Farber
Cancer Institute Animal Care and Use Committee (Animal Welfare Assurance number A3023-01) or by the
Department of Animal Medicine of the University of Massachusetts Animal Care and Use Committee
(Animal Welfare Assurance number A2420-13). All mice were bred and maintained using standard
humane animal husbandry protocols. Mice infected with M. tuberculosis were housed in a biosafety level
3 facility under speciﬁc-pathogen-free conditions in animal biohazard containment suites (Dana Farber
Cancer Institute, Boston, MA, and University of Massachusetts, Worcester, MA). Collection of the human
blood samples was approved by the Institutional Review Board of Shenzhen Third People’s Hospital
(ethical approval number 2016-006), and the methods were performed in accordance with the approved
guidelines of the institution. All subjects were adults, and written informed consent was obtained from
all participants.
Mice. C57BL/6J (WT) and B6.129S7-Rag1/J (RAG/) mice were obtained from Jackson Laboratories.
C57BL/6J GM-CSF/ mice were provided by Glenn Dranoff. C57BL/6J PPARﬂ/ﬂ;LysMcre/ (PPAR/)
and PPARﬂ/ﬂ; LysMcre/ (PPARﬂ/ﬂ control) mice were provided by Glenn Dranoff.
Reciprocal bone marrow chimeras. Bone marrow chimeras were made by lethally irradiating
CD45.2 GM-CSF/ mice and C57BL/6J WT recipients (2 doses of 600 rad separated by 3 h). BM was
ﬂushed from the femurs, tibia, and humeri of donor mice (CD45.1 GM-CSF/ mice and C57BL/6J WT
mice), and red blood cells were lysed. Each recipient mouse received a total of 107 BM cells via lateral
tail vein injection and was kept on antibiotic-containing water for 5 weeks following irradiation. Mice
were checked for reconstitution to assess the ratio of donor cells in the peripheral blood by ﬂow
cytometry. BM chimeras were infected with M. tuberculosis 8 to 10 weeks after transfer of the BM cells
(76).
In vivo aerosol infections. In vivo infections were performed using virulent M. tuberculosis (Erdman
strain). For each infection, a bacterial aliquot was thawed, sonicated twice for 10 s, and then diluted in
0.9% NaCl–0.02% Tween 80. A 15-ml suspension of M. tuberculosis was loaded into a nebulizer
(MiniHEART nebulizer; Vortran Medical Technology); mice were infected via the aerosol route with a
nose-only exposure unit (Intox Products) and received ~50 to 100 CFU/mouse. Alternatively, mice were
infected using a Glas-Col inhalation exposure system (Terre Haute, IN). Mice were euthanized by CO2
inhalation, and lungs were aseptically removed after perfusion of 10 ml of sterile RPMI medium into the
right ventricle of the heart. Lung mononuclear cells were obtained by mechanical disruption using a
gentleMACS dissociator (Miltenyi Biotec, Inc.) followed by incubation in collagenase (Sigma-Aldrich) for
30 min at 37°C. Cells were isolated by forcing suspensions through a 70-m cell strainer and then
enumerated in 4% trypan blue by using a hemacytometer.
T cell adoptive transfer. For bulk T cell transfers, naive T cells were isolated from the spleen and
lymph nodes of WT and GM-CSF/ mice and then separated using the pan T cell isolation kit (Miltenyi
Biotec, Inc.) following the manufacturer’s protocol. A total of 5  106 T cells were then injected
intravenously (i.v.) via tail vein into each RAG/ recipient. All mice were infected with M. tuberculosis
Erdman strain via the aerosol route within 24 h of cell transfer. For CD4 T cell cotransfer experiments,
immune CD4 T cells from the lungs of WT (CD45.1) and GM-CSF KO (CD45.2) mice infected by aerosol
with M. tuberculosis Erdman strain for 4 weeks were puriﬁed by positive separation with anti-CD4
magnetic beads using an autoMACS Pro separator (Miltenyi Biotec, Inc.). Cell purity was consistently
95% for WT CD4 T cells and 85% for GM-CSF KO CD4 T cells. CD4 cells (106 of each genotype)
were injected i.v. into recipient GM-CSF/ mice that had been sublethally irradiated 24 h before with
600 rad from a cesium 137 source. Within 24 h of cell transfer, recipient mice were infected with
aerosolized M. tuberculosis Erdman. For cotransfer experiments, immune CD4 T cells from the lungs of
WT (CD45.1) and GM-CSF KO (CD45.2) mice were cotransferred (106 each) into sublethally irradiated WT
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CD90.1 recipients, which were then infected with aerosolized M. tuberculosis Erdman, following the
protocol described above.
Flow cytometry and ICS. For ICS stimulation, cells were plated in a 96-well plate and incubated for
4 to 5 h at 37°C with IL-2 in either the absence of stimuli or in the presence of TB10.44-11 peptide (10 M;
New England Peptide), ESAT61-20 peptide (10 M; New England Peptide), or anti-CD3/anti-CD28 (1 g/
ml; BioLegend). Brefeldin A (GolgiPlug; BD Biosciences) was added to the cultures 1 h after the addition
of exogenous stimuli. Cells were next incubated with CD16/CD32 (FcBlock; BD Biosciences). Surface
staining included antibodies for murine TCR- (H57-597), TCR- (UC7-13D5), CD3 (17A2), CD19 (6D5),
CD4 (RM4-5), CD8 (53-6.7), CD25 (PC61), CD69 (H1.2F3), CD11b (M1/70), CD11c (N418), Ly6C (HK1.4), Ly6G
(1A8), and isotype controls (all from BioLegend). Except for iNKT cell staining, ICS with antibodies speciﬁc
for mouse GM-CSF (MP1-22E9; EBioscience) and IFN- (XMG1.2; BioLegend) was performed in Perm/Wash
buffer (BD Biosciences) following ﬁxation and permeabilization with Fix/Perm buffer (BD Biosciences).
PBS-57-loaded and control phycoerythrin- and allophycocyanin-conjugated CD1d tetramers were pro-
vided by the National Institute of Allergy and Infectious Diseases Tetramer Facility (Emory University
Vaccine Center). For iNKT cells, after tetramer staining, ICS with antibodies speciﬁc for mouse GM-CSF and
IFN- (see above) was performed following ﬁxation with 4% paraformaldehyde and permeabilization
with Perm/Wash buffer (BD Biosciences). Data were collected using FACSCanto (BD Biosciences) or
MACSQuant (Miltenyi Biotec, Inc.) systems and analyzed with FlowJo software (Tree Star, Inc.).
Human TB patients and healthy controls. Healthy adults (n  9) and patients with TB (n  9) were
recruited from Shenzhen Third People’s Hospital. For all subjects, a medical history was taken and a
physical examination was performed with routine clinical investigations, including HIV serology, chest
radiography, IFN- release assays, and microbiological sputum examination, whenever possible. Patients
with HIV infection were excluded. Case deﬁnitions were as follows: (i) HC had a negative chest X-ray, no
evidence of TB, no history of TB, and negative results for an M. tuberculosis-speciﬁc IFN- enzyme-linked
immunosorbent spot (ELISPOT) assay (77). (ii) All recruited TB patients had symptoms and chest
computed tomography results suggestive of pulmonary TB, as well as a positive sputum M. tuberculosis
culture. The mean age of each group (with interquartile range) was as follows: HC, 44 years (25 to 79);
TB, 40 years (25 to 68). The male:female ratio of each group was 5:4 for HC and 5:4 for the TB group.
Human cell preparation and in vitro stimulation. PBMC were isolated from whole blood as
described previously (78). PBMC were cultured in complete RPMI 1640 medium at a ﬁnal concentration
of 106/ml with PMA and ionomycin (50 ng/ml and 1 mg/ml; Sigma-Aldrich, USA) for 2 h in a 24-well plate
at 37°C in 5% CO2. Brefeldin A (10 mg/ml; Sigma-Aldrich) was then added and the incubation was
continued for an additional 4 h. To measure antigen-speciﬁc cytokine production, heat-killed M. tuber-
culosis lysate (10 mg/ml) was added to the PBMC for 4 h, and then brefeldin A was added and the cells
were cultured for an additional 12 h. PBMC incubated with no stimulation served as negative controls.
After 16 h of culture, cells were stained with surface and intracellular cytokine antibodies for ﬂow
cytometric analysis as described below. Monoclonal antibodies against human IFN- (4S.B3) and GM-CSF
(BVD2-21C11) were obtained from BioLegend. All other reagents were obtained from BD Biosciences,
including monoclonal antibodies against human CD3 (SK7), CD4 (SK3), and isotype-matched control
immunoglobulins. After stimulation, cells were washed twice with phosphate-buffered saline (PBS) and
ﬁxed in BD ﬂuorescence-activated cell sorting (FACS) lysing solution followed by permeabilization using
FACS permeabilizing solution and then stained for the intracellular cytokines and molecules with
antibodies diluted in PBS buffer. Lymphocytes were gated on forward- and side-scatter proﬁles. At least
0.2 million events were acquired using a FACSCanto system (Becton, Dickinson, San Jose, CA, USA) and
analyzed using FACSDiva software (version 5.0.2).
Macrophage isolation and culture. Thioglycolate-elicited peritoneal macrophages were lavaged 4
to 5 days after 3% intraperitoneal thioglycolate injection and then isolated by positive selection with
CD11b microbeads and LS magnetic columns (Miltenyi Biotec, Inc.). Puriﬁed cells were over 95% F4/80
CD11b, as determined by ﬂow cytometry. Macrophages were seeded at 1  105 in 96-well culture
plates in complete RPMI 1640 medium (Invitrogen Life Technologies, Inc.) supplemented with 10% fetal
calf serum (HyClone).
M. tuberculosis in vitro culture and infection. H37Rv was grown and prepared as previously
described (59). Bacteria were counted and added to macrophages at an effective multiplicity of infection
(MOI) of 0.2 for CFU experiments for 2 h. Cultures were washed three times to remove extracellular
bacteria. Infected macrophages were cultured overnight, and cytokines were added on day 1. For CFU
measurements, cells were lysed with 1% Triton X-100–PBS, and lysates from quadruplicate conditions
were plated in serial dilutions on Middlebrook 7H10 agar plates (Thermo Fisher Scientiﬁc) and cultured
at 37°C for 21 days. Infected macrophages were treated with the following reagents: recombinant murine
GM-CSF and IFN- (PeproTech).
CFU reduction determinations. To compare inhibition of bacterial growth across multiple
experiments, the percent CFU reduction was calculated. One hundred percent CFU reduction on day
5 indicated complete inhibition of bacterial growth from day 1 levels, while 0% CFU reduction
indicated no change in bacterial growth from untreated macrophages. The following formula was used:
percent CFU reduction 100 {[CFU(untreated mf day 5)CFU(treated mf day 5)]/[CFU(untreated mf day 5)CFU(untreated
mf day 1)]}, where “mf” is macrophages.
Bioplex immunoassay. Protein from lung homogenates was extracted using the Bio-Plex cell lysis
kit (Bio-Rad) and ﬁltered through a 0.2-m ﬁlter to remove any bacteria. The concentration of GM-CSF
was measured using a mouse Bio-Plex cytokine assay in accordance with the manufacturer’s instructions
(Bio-Rad).
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Statistical analysis. All data are presented as means SEM. Data were analyzed by one-way ANOVA
(with 95% conﬁdence intervals) and Dunnett’s posttest (for comparison against a single control) or
unpaired Student’s t test. Analysis was performed using GraphPad Prism software.
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